



Novel Method for the Inhibition of Estrogen-Dependent Breast Cancer

Competitive advantage

The invention can be used for:

- Prognosis of which estrogen-dependent breast cancers have increased risk to progress into estrogen-independent one
- Treatment of estrogen-dependent breast cancer
- Prevention of progression of estrogen-dependent breast cancer into estrogen-independent one

Application and market areas


- Pharmaceutical companies

Technical description

Many estrogen-dependent breast cancers transform to estrogen-independent one during antiestrogen and other endocrine therapies. Novel micro RNAs (miRNA) have been identified for the negative regulation of Estrogen Receptor Alpha (ER α) expression and the efficient inhibition of the ER α function.

Intellectual property

Patent pending FI20095227 "Nucleic acids regulating oestrogen receptor (ER)-alpha signaling in breast cancer"



Why partner with VTT?

5 reasons for technology partnering with VTT

1. New business and product concepts based on strong IP and world class research
2. Global R&D partnership with 50 Fortune 500 companies
3. Market driven multi-disciplinary solutions
4. Portfolio of more than 1,000 patents and inventions
5. Combined experience of more than 2,000 motivated researchers in eight focused areas of technology

Additional information

VTT Technical Research Centre of Finland
Timo Pulli, PhD
Business Development Manager
Tel: +358 20 722 5107
timo.pulli@vtt.fi
P.O. Box 1000, FI-02044 VTT, Finland